Illumina Releases Latest Annual Corporate Social Responsibility Report Highlighting ESG Progress and Commitment to Improving Human Health

San Diego, California, USAJune 6, 2023PR Newswire -- June 5, 2023, Illumina (NASDAQ: ILMN), the global leader in gene sequencing and chip technology, released its annualCorporate Social Responsibility (CSR) Report, focusing on showcasing the company's firm commitment to "dedicated to improving human health" and the progress of Environmental, Social, and Governance (ESG) projects throughout 2022.

Illumina Releases Its Latest Annual Corporate Social Responsibility Report

"Genomics has the potential to elevate global healthcare, promote sustainability and equity by improving diagnosis and treatment; enhance the representativeness of genomic data, increase the accessibility of personalized medicine, and deepen the understanding of the world," said Francis deSouza, CEO of Illumina. "Guided by our corporate mission, we are actively implementing commercial strategies and taking robust, meaningful actions to accelerate the accessibility of genomics, empower communities, integrate the concept of environmental sustainability, cultivate talent, and operate responsibly."

Illumina's ESG program is rooted in five key focus areas, and the latest annual CSR report also highlights the significant progress the company has made in each area:

To read the full report, please visitIllumina Official Website CSR Special PageThe company will host its third annual ESG Investor Online Event on June 12.Click hereSign up.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding authorizations, future plans, business strategies, and other non-historical statements. These statements are based on Illumina's views, expectations, and assumptions about future events, business performance, and plans at the time the statements are made. Such forward-looking statements may be accompanied by words or phrases such as "anticipate," "believe," "can," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "projecting," "target," "will," and other terms of similar meaning. Unless required by applicable law or regulation, Illumina is under no obligation to update these statements, and undue reliance should not be placed on forward-looking statements. Specific factors are disclosed under the "Risk Factors" section in Illumina’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, in disclosures made during publicly announced conference calls, the dates and times of which are provided in advance, and in filings with the U.S. Securities and Exchange Commission, including Quarterly Reports on Form 10-Q.

About Illumina

Illumina, Inc. is committed to driving and inspiring the development of genomics with the goal of continuously improving human health. In 2023, we celebrate 25 years of innovation, and it is this dedication to innovation that has made us a global leader in sequencing and array technologies, providing specialized services to customers in research, clinical, and applied markets worldwide. Our products are widely used in life sciences, oncology, reproductive health, agriculture, and other emerging fields. For more information, please visitillumina.com.cnOr follow the Illumina WeChat Official Account.